Arbutus Biopharma Corp
Gesloten
5 0.2
Overzicht
Wijziging aandelenprijs
24u
Min
4.99
Max
5.04
Inkomsten | -175M -5.1M |
|---|---|
Verkoop | -178M 1M |
K/W Sectorgemiddelde | 6.494 56.432 |
EPS | -0.03 |
Winstmarge | -507.199 |
Werknemers | 19 |
EBITDA | -175M -5.1M |
Volgende Winsten | 12 nov 2026 |
|---|
Marktkapitalisatie | 110M 1B |
|---|---|
Vorige openingsprijs | 4.8 |
Vorige sluitingsprijs | 5 |
Arbutus Biopharma Corp Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Arbutus Biopharma Corp Prognose
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.